Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Panel: Broaden Opioids Risk Plans, Require Prescriber Training

Executive Summary

An FDA panel of expert advisers unanimously agreed the risk plans for opioids need to be significantly changed – with most calling for them to cover immediate-release products, rather than just the extended-release and long-acting drugs. Most on the committee also insisted prescriber training should be mandatory, rather than voluntary.

Advertisement

Related Content

Califf Confronts Opioids Challenge
Pills, Bills, Capitol Hill: Congrats Califf, It's All Yours
FDA Opioids Plan Not Enough To Unblock Califf
FDA kicks 'moderate' out of ER/LA opioid pain indication
After 3+ years, US FDA finalizes strict ER/LA opioid REMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel